HC Wainwright Reiterates “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Thursday, MarketBeat Ratings reports. They presently have a $120.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 38.27% from the stock’s previous close.

ORKA has been the topic of a number of other research reports. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. UBS Group lifted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Wedbush reissued an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $128.91.

Oruka Therapeutics Trading Down 3.5%

Shares of ORKA traded down $3.15 during mid-day trading on Thursday, reaching $86.79. The company had a trading volume of 232,094 shares, compared to its average volume of 1,097,900. The stock has a market cap of $5.75 billion, a price-to-earnings ratio of -42.67 and a beta of -0.34. The firm has a fifty day simple moving average of $96.79 and a 200-day simple moving average of $75.32. Oruka Therapeutics has a fifty-two week low of $14.89 and a fifty-two week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, equities analysts predict that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Arjun Agarwal sold 533 shares of Oruka Therapeutics stock in a transaction on Monday, September 21st. The shares were sold at an average price of $95.75, for a total transaction of $51,034.75. Following the sale, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,361,469.25. The trade was a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the sale, the insider directly owned 31,771 shares in the company, valued at $2,935,004.98. This trade represents a 20.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 122,950 shares of company stock valued at $11,528,806 in the last quarter. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Oruka Therapeutics during the 2nd quarter worth $474,916,000. Jupiter Topco LLC acquired a new position in Oruka Therapeutics during the 2nd quarter worth $130,968,000. Remedium Capital Partners LLC grew its holdings in Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after acquiring an additional 13,247 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Oruka Therapeutics by 16.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after acquiring an additional 208,480 shares in the last quarter. Finally, Avidity Partners Management LP grew its holdings in Oruka Therapeutics by 15.1% during the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after acquiring an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial potential upside from the referenced $89.93 level. Tickerreport analyst rating article
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $120 price target, indicating continued analyst confidence in Oruka’s pipeline and valuation. StreetInsider analyst rating article
• Positive Sentiment: Oruka reported encouraging Week 28 results from the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 responses increased to 71.4% and PASI 90 responses to 87.3%, despite no additional dosing after Week 4, suggesting durable and deepening treatment effects. Oruka EVERLAST-A Week 28 results
• Positive Sentiment: Placebo-crossover patients achieved PASI 90 and PASI 100 response rates comparable to patients initially treated with ORKA-001, while the therapy continued to show a favorable safety and tolerability profile. Additional EVERLAST-A data are expected in December 2026, with EVERLAST-B results expected in the fourth quarter. MarketScreener trial results
• Negative Sentiment: Oruka shares fell after the Week 28 release despite improving psoriasis responses. The reaction suggests investors may have already anticipated strong data, or may be focused on the need for additional validation from upcoming 52-week and follow-on trial results. Yahoo Finance market reaction

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.